X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (15001) 15001
Book Chapter (81) 81
Magazine Article (51) 51
Dissertation (49) 49
Newspaper Article (29) 29
Publication (17) 17
Conference Proceeding (16) 16
Book / eBook (6) 6
Government Document (6) 6
Web Resource (6) 6
Reference (4) 4
Trade Publication Article (2) 2
Book Review (1) 1
Newsletter (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
trastuzumab (12589) 12589
humans (10024) 10024
female (7552) 7552
oncology (7391) 7391
breast cancer (6314) 6314
breast neoplasms - drug therapy (4931) 4931
chemotherapy (3712) 3712
cancer (3602) 3602
breast neoplasms - pathology (3286) 3286
middle aged (3159) 3159
antibodies, monoclonal, humanized (2973) 2973
receptor, erbb-2 - metabolism (2903) 2903
her2 (2769) 2769
antineoplastic agents - therapeutic use (2559) 2559
adult (2522) 2522
aged (2485) 2485
therapy (2332) 2332
breast neoplasms - metabolism (2084) 2084
animals (2012) 2012
antineoplastic combined chemotherapy protocols - therapeutic use (1961) 1961
antibodies, monoclonal - therapeutic use (1811) 1811
cell line, tumor (1692) 1692
treatment outcome (1681) 1681
breast neoplasms - genetics (1622) 1622
metastasis (1616) 1616
survival (1589) 1589
adjuvant chemotherapy (1559) 1559
care and treatment (1547) 1547
receptor, erbb-2 - genetics (1531) 1531
prognosis (1524) 1524
monoclonal-antibody (1457) 1457
breast-cancer (1435) 1435
skin and connective tissue diseases (1431) 1431
erbb-2 protein (1396) 1396
expression (1396) 1396
tumors (1357) 1357
mice (1291) 1291
epidermal growth factor (1259) 1259
research (1254) 1254
immunohistochemistry (1195) 1195
medicine & public health (1195) 1195
cancer therapies (1132) 1132
receptor, erbb-2 - antagonists & inhibitors (1123) 1123
analysis (1118) 1118
lapatinib (1114) 1114
pharmacology & pharmacy (1108) 1108
antineoplastic agents - pharmacology (1074) 1074
male (975) 975
aged, 80 and over (950) 950
disease-free survival (923) 923
paclitaxel (921) 921
neoplasm staging (911) 911
docetaxel (910) 910
antibodies, monoclonal - administration & dosage (895) 895
health aspects (894) 894
drug therapy (885) 885
antibodies, monoclonal, humanized - therapeutic use (877) 877
efficacy (877) 877
gene amplification (872) 872
breast neoplasms - mortality (871) 871
antineoplastic agents - adverse effects (867) 867
metastatic breast-cancer (860) 860
chemotherapy, adjuvant (859) 859
open-label (856) 856
resistance (823) 823
monoclonal antibodies (820) 820
receptor (820) 820
patients (818) 818
pertuzumab (801) 801
phase-ii (793) 793
neoplasms (778) 778
receptor, erbb-2 - analysis (769) 769
antibodies, monoclonal, humanized - administration & dosage (764) 764
retrospective studies (764) 764
neoadjuvant therapy (761) 761
antineoplastic agents (757) 757
growth-factor receptor (754) 754
neoplasm metastasis (750) 750
cardiotoxicity (748) 748
trial (744) 744
clinical trials (708) 708
carcinoma (705) 705
antibodies, monoclonal - pharmacology (704) 704
hematology, oncology and palliative medicine (697) 697
metastases (695) 695
women (692) 692
breast neoplasms - therapy (689) 689
proteins (688) 688
amplification (687) 687
antineoplastic agents - administration & dosage (685) 685
cell biology (682) 682
trastuzumab resistance (677) 677
herceptin (666) 666
gene expression (653) 653
antimitotic agents (651) 651
safety (646) 646
trastuzumab - administration & dosage (641) 641
surgery (634) 634
trastuzumab - therapeutic use (633) 633
doxorubicin (626) 626
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (14368) 14368
Japanese (311) 311
French (307) 307
German (179) 179
Chinese (101) 101
Spanish (58) 58
Russian (50) 50
Portuguese (44) 44
Polish (38) 38
Italian (30) 30
Hungarian (18) 18
Czech (16) 16
Korean (16) 16
Norwegian (9) 9
Turkish (9) 9
Dutch (8) 8
Danish (5) 5
Finnish (5) 5
Swedish (5) 5
Hebrew (4) 4
Slovak (3) 3
Slovenian (3) 3
Bosnian (2) 2
Serbian (2) 2
Bulgarian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nippon Shōkakibyō Gakkai zasshi, ISSN 0446-6586, 2017, Volume 114, Issue 1, pp. 59 - 68
Journal Article
Annals of oncology, ISSN 0923-7534, 2018, Volume 29, Issue 3, pp. 646 - 653
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2017, Volume 389, Issue 10075, pp. 1195 - 1205
Journal Article
British journal of clinical pharmacology, ISSN 0306-5251, 12/2017, Volume 83, Issue 12, pp. 2767 - 2777
Aims We conducted population pharmacokinetic (PopPK) and exposure–response analyses for trastuzumab emtansine (T‐DM1), to assess the need for T‐DM1 dose... 
population pharmacokinetics (PopPK) | exposure–response (E‐R) | trastuzumab emtansine (T‐DM1) | metastatic breast cancer | exposure–response (E-R) | trastuzumab emtansine (T-DM1) | exposure-response (E-R) | SOLID TUMORS | MODELS | CAUSAL INFERENCE | PHARMACOLOGY | PHARMACOLOGY & PHARMACY | GUIDE | Antineoplastic Agents, Immunological - administration & dosage | Antineoplastic Agents, Immunological - pharmacokinetics | Area Under Curve | Trastuzumab - pharmacokinetics | Humans | Receptor, ErbB-2 - metabolism | Ado-Trastuzumab Emtansine | Metabolic Clearance Rate | Trastuzumab - blood | Antineoplastic Agents, Immunological - blood | Breast Neoplasms - enzymology | Tubulin Modulators - administration & dosage | Female | Receptor, ErbB-2 - antagonists & inhibitors | Maytansine - blood | Tubulin Modulators - blood | Maytansine - adverse effects | Tubulin Modulators - adverse effects | Risk Assessment | Maytansine - analogs & derivatives | Tubulin Modulators - pharmacokinetics | Kaplan-Meier Estimate | Proportional Hazards Models | Trastuzumab - adverse effects | Logistic Models | Treatment Outcome | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Agents, Immunological - adverse effects | Maytansine - administration & dosage | Models, Biological | Maytansine - pharmacokinetics | Breast Neoplasms - blood | Breast Neoplasms - mortality | Infusions, Intravenous | Nonlinear Dynamics | Pharmacokinetic Dynamic Relationships
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 917 - 928
Summary Background CT-P6 is a proposed biosimilar to reference trastuzumab. In this study, we aimed to establish equivalence of CT-P6 to reference trastuzumab... 
Hematology, Oncology and Palliative Medicine | NEOADJUVANT TREATMENT | EPIRUBICIN | ONCOLOGY | CONTROLLED SUPERIORITY TRIAL | OPEN-LABEL | PLUS TRASTUZUMAB | CHEMOTHERAPY | BIOSIMILAR MONOCLONAL-ANTIBODIES | PATHOLOGICAL COMPLETE RESPONSE | ADJUVANT TRASTUZUMAB | PACLITAXEL | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Adenocarcinoma - pathology | Febrile Neutropenia - chemically induced | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Breast Neoplasms - chemistry | Fluorouracil - administration & dosage | Mastectomy | Adult | Female | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Adenocarcinoma - chemistry | Biosimilar Pharmaceuticals - therapeutic use | Biosimilar Pharmaceuticals - administration & dosage | Double-Blind Method | Trastuzumab - adverse effects | Trastuzumab - administration & dosage | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Biosimilar Pharmaceuticals - adverse effects | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Receptor, ErbB-2 - analysis | Neoplasm Staging | Adenocarcinoma - surgery | Antimitotic agents | Medical colleges | Adjuvant treatment | Clinical trials | Breast cancer | Product development | Comparative analysis | Antineoplastic agents | Cancer
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 2, pp. 122 - 131
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 4, pp. 545 - 554
Journal Article
Journal Article
Journal Article